Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens

Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens

Blog Article

It is hypothesized that SARS-CoV-2 has the potential to elicit autoimmunity due to #felt saddle pad molecular mimicry between immunogenic proteins of the virus and human extracellular molecules.While in silico and in vitro evaluation of such immune cross-reactivity of human antibodies to SARS-CoV-2 proteins with several different tissue antigens has been described, there is limited information specifically pertaining to the immunological effects of COVID-19 and vaccines against SARS-CoV-2 on the development of autoimmune bullous diseases (AIBDs).Twelve seropositive post-COVID-19 individuals and 12 seropositive healthy volunteers who received two doses of the mRNA COVID-19 vaccine from copyright-BioNTech have been included in this case series investigation.Serum samples of these blood donors were tested for autoantibodies to the main immunobullous autoantigens, i.e.

, desmoglein 1, desmoglein Start Relay 3, envoplakin, BP180, BP230, and type VII collagen.Our study revealed that none of the 24 anti-SARS-CoV-2 IgG-positive subjects had concomitant antibody reactivity with any of the tested autoantigens.These results argue against a relationship between SARS-CoV-2 infection/vaccines and AIBDs with respect to disease-triggering antibody cross-reactivity.